Media stories about Aegerion Pharmaceuticals (NASDAQ:AEGR) have trended somewhat negative this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aegerion Pharmaceuticals earned a media sentiment score of -0.02 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.5224954819135 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Aegerion Pharmaceuticals (NASDAQ AEGR) remained flat at $$1.97 during mid-day trading on Friday. Aegerion Pharmaceuticals has a 1-year low of $1.23 and a 1-year high of $10.85. The firm has a market cap of $56.69, a P/E ratio of -0.33 and a beta of 0.50. The company has a current ratio of 1.02, a quick ratio of 0.67 and a debt-to-equity ratio of -19.22.
COPYRIGHT VIOLATION NOTICE: “Aegerion Pharmaceuticals (NASDAQ:AEGR) Getting Somewhat Critical Media Coverage, Report Shows” was posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://baseballnewssource.com/2018/03/17/aegerion-pharmaceuticals-aegr-getting-somewhat-critical-press-coverage-report-shows/2002260.html.
Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.
Receive News & Ratings for Aegerion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.